Kevan Shokat

Professor

UCSF Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kevan Shokat is a Professor at UCSF Medical Center in the United States. His research focuses on oncogenic signaling pathways, particularly in relation to RAS mutations, and the development of targeted therapies for cancer treatment. His recent publications emphasize innovative approaches to drugging challenging targets and understanding the molecular mechanisms of oncogenic proteins.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Jonathan Ostrem

Assistant Professor

University of California, San Francisco

UNITED STATES

View details

Ross Cagan

Regius Professor

University of Glasgow

UNITED KINGDOM

View details

Hayden Peacock

University of Tokyo

JAPAN

View details

Ziyang Zhang

Assistant Professor

UC Berkeley College of Chemistry

UNITED STATES

View details

Maria Barna

Stanford University School of Medicine

UNITED STATES

View details

William A. Weiss

University of California

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevan Shokat

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Introduction: Drugging the Undruggable

Deazaguanylation is a nucleobase-protein conjugation required for type IV CBASS immunity

Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells

Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells

Direct RAS inhibitors turn 10

Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D

The structure of KRAS G12C bound to divarasib highlights features of potent switch-II pocket engagement

Evolutionarily divergent mTOR remodels translatome for tissue regeneration

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability

Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)

Brain-restricted mTOR inhibition with binary pharmacology

Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile

Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy

State-selective modulation of heterotrimeric Gαs signaling with macrocyclic peptides

Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1

Drugging the Next Undruggable KRAS Allele-Gly12Asp

Drugging the undruggable: Ross Cagan interviews Kevan Shokat

Collaborators (6)

Jonathan Ostrem

Ross Cagan

Hayden Peacock

Ziyang Zhang

Maria Barna

William A. Weiss

Make your next move.